Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus ORETON.
DEPO-TESTOSTERONE vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
50-400 mg IM every 2-4 weeks
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category D/X
Category C
Androgen
Androgen